Structure via PubChem · Public domain (PubChem)
gadoteridol
Sign in to saveAlso known as Gd-hpdo3a, Gadolinium 2,2',2''-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate, Gadolinium-HP-do3a, GD-HP-do 3a, Prohance, Prohance Multipack, SQ-32692
Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance. Gadoteridol was first approved for use in the United States in 1992.
Chemical data
- Formula
- C17H29GdN4O7
- Molecular weight
- 558.7 g/mol
- IUPAC name
- 2-[4,7-bis(carboxylatomethyl)-10-(2-hydroxypropyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+)
- SMILES
- CC(CN1CCN(CCN(CCN(CC1)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])O.[Gd+3]
- InChIKey
- DPNNNPAKRZOSMO-UHFFFAOYSA-K
- Polar surface area
- 154 Ų
- H-bond donors
- 1
- H-bond acceptors
- 11
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1992
- Admin. routes
- parenteral
- Indications
- glioblastoma multiforme, anaplastic astrocytoma, chronic progressive multiple sclerosis, secondary progressive multiple sclerosis
via ChEMBL · EBI
Research
679 papers- Clinical Safety of Gadoteridol, Representative of the Macrocyclic Class of Gadolinium-Based Contrast Agents.Journal of magnetic resonance imaging : JMRI · 2020
- Gadoteridol-enhanced MRI of the breast: can contrast agent injection rate impact background parenchymal enhancement?Acta radiologica (Stockholm, Sweden : 1987) · 2022
- Gadolinium-Induced Fibrosis.Annual review of medicine · 2016
- Physicochemical properties of gadoteridol and other magnetic resonance contrast agents.Investigative radiology · 1992
- Stability testing of gadoteridol and gadobenate dimeglumine formulations under exposure to high-intensity focused ultrasound.The British journal of radiology · 2022
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 559.127728
- Has use
- medication
Show 5 more facts
- chemical formula
- C₁₇H₂₉GdN₄O₇
- canonical SMILES
- CC(CN1CCN(CCN(CCN(CC1)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])O.[Gd+3]
- World Health Organisation international non-proprietary name
- gadoteridol
- subject has role
- contrast agent
- legal status (medicine)
- boxed warning
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance. Gadoteridol was first approved for use in the United States in 1992.
==References==
Excerpted from Wikipedia’s “gadoteridol” article, available under the CC BY-SA 4.0 licence.